Quarterly report · Q3
4671.TEDINET S100SUJL
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥32.3bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥46.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥35.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥2.5bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥1.6bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.9bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.3bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.3bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥36.9bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥38.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥38.3bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.1bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥12.3bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥25.8bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥24.7bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.0bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.6bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥115.04 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.3 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥215.29 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.88 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.43 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥114.58 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥214.03 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥146.23 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 69.7% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥377m |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥19.6bn |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥19.6bn |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥0 |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥12.0bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥12.0bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥0 |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥661m |
| jpcrp040300-q3r_E04982-000ICT Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥716m |
| jpcrp040300-q3r_E04982-000ICT Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥716m |
| jpcrp040300-q3r_E04982-000ICT Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥71m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥32.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥32.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥0 |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥6m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥362m |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥23.4bn |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥23.4bn |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5m |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.5bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥12.0bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥12.0bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥590m |
| jpcrp040300-q3r_E04982-000ICT Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥469m |
| jpcrp040300-q3r_E04982-000ICT Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥469m |
| jpcrp040300-q3r_E04982-000ICT Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥170m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥35.9bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥35.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 363
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 19593000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 12004000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E04982-000ICTBusinessReportableSegmentsMember | 716000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 32314000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 32314000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E04982-000ICTBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -0 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 19593000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 12005000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E04982-000ICTBusinessReportableSegmentsMember | 716000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 32315000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -0 | JPY |
| Net sales | CurrentYTDDuration | 32314000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 1088000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 661000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E04982-000ICTBusinessReportableSegmentsMember | 71000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 1821000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -377000000 | JPY |
| Operating income | CurrentYTDDuration | 1443000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-02-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第37期第３四半期（自 令和５年10月１日 至 令和５年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ファルコホールディングス | |
| Company name in english cover page | FilingDateInstant | FALCO HOLDINGS Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長執行役員 安田 忠史 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)京都市左京区聖護院蓮華蔵町44番地３（同所は登記上の本店所在地で実際の管理業務は「最寄りの連絡場所」で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | － | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | － | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪市中央区内平野町１丁目３番７号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０６－７６３２－６１５０ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員管理室長 大馬 久幸 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E04982 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 46710 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ファルコホールディングス | |
| Filer name in english | FilingDateInstant | FALCO HOLDINGS Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |